Actively Recruiting
Autobiographical Memory in Opioid Use Disorder
Led by University of Pennsylvania · Updated on 2025-08-29
30
Participants Needed
1
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The research study is being conducted to better understand memory function in people with opioid use disorder (OUD) and whether memory training can improve the symptoms and lives of people with OUD. Further, this study seeks to identify how brain and heart activity contribute to memory function and OUD symptoms. Participants will be asked to complete a baseline assessment, four weeks of at-home memory training (MemFlex), and a post-treatment follow-up assessment. Everyone enrolled will receive MemFlex as there is no placebo group. Each visit will include collection of a urine sample for drug testing. During the baseline and follow-up assessments, researchers will collect brain information using functional near-infrared spectroscopy (fNIRS) and heartbeat data using a wearable wristband sensor. MemFlex is a cognitive-behavioral intervention that does not pose any risk. However, the use of MemFlex in this study is experimental as it has not been tested in individuals with OUD. We will enroll 20 participants with OUD and 10 participants meeting healthy volunteer criteria.
CONDITIONS
Official Title
Autobiographical Memory in Opioid Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years to 60 years old.
- Willingness to provide signed, informed consent and commit to completing study procedures.
- Ability and willingness to comply with scheduled visits, treatment plans, lab tests, and other procedures.
- Access to a cellphone.
- Lifetime self-reported history of opioid use disorder according to DSM-5 criteria.
- Stable dose of medication for opioid use disorder for at least 2 weeks.
- Access to a stable residence or space to complete at-home treatment.
You will not qualify if you...
- Current severe psychiatric or physical disorder that significantly interferes with brain function or safety.
- Head trauma or injury likely affecting the prefrontal cortex (e.g., extended loss of consciousness, skull fracture, intracranial bleeding).
- Medical conditions or treatments interfering with ability to complete the intervention.
- Inability to sit upright, remain still, and operate a mouse and keypad.
- Participation in another research study or clinical trial with investigational drugs within 30 days.
- Currently prescribed opioid medications for pain or other disorders besides opioid use disorder.
- Past 1-year history of non-opioid substance use disorder, except nicotine, alcohol, or cannabis.
- Positive urine drug screen for substances other than opioids, cocaine, or cannabis at screening or baseline.
- For healthy volunteers: lifetime history of substance use disorders (except nicotine use disorder anytime and remote alcohol or cannabis use disorders).
- For healthy volunteers: positive urine drug screen at screening or baseline.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
M
Megan Ivey, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here